Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

pembrolizumab 38Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Standard of Care 17Nivolumab 17Carboplatin 16Exercise 15Paclitaxel 14atezolizumab 13Gemcitabine 13Pemetrexed 12Cisplatin 12Fluorouracil 11Doxorubicin 11Radiotherapy 10Cetuximab 10Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9Biopsy 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Prednisone 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Cytochrome P-450 CYP2B6 × 90 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡